Allspring SMID Core ETF (ASCE)
About this ETF
ASCE is actively managed and invests primarily in equity securities of small- and medium-cap US companies, within the Russell 2500 Index range. Up to 20% of total assets may be allocated to foreign issuers in developed markets, including ADRs. The fund combines quantitative methods with qualitative analysis in selecting companies believed to be relatively undervalued with possible future earnings. The quantitative method is based on a proprietary alpha model which ranks securities based on valuation, quality, and momentum. The qualitative analysis, on the other hand, includes management evaluation, products, competition, and risk. A focused portfolio of approximately 50 securities diversified across major sectors is curated, avoiding issuers with significant alcohol, gaming, or tobacco business. Cash or money market instruments may…
Price
Top 10 holdings
| Corcept Therapeutics Incorporated. CORT | 3.06% |
| Blue Bird Corporation BLBD | 2.95% |
| Virtu Financial, Inc. Class A VIRT | 2.83% |
| Amneal Pharmaceuticals, Inc. Class A AMRX | 2.73% |
| Exelixis, Inc. EXEL | 2.65% |
| Acadian Asset Management Inc. AAMI | 2.60% |
| TTM Technologies, Inc. TTMI | 2.44% |
| Carpenter Technology Corporation CRS | 2.41% |
| StoneX Group Inc. SNEX | 2.34% |
| SkyWest, Inc SKYW | 2.28% |
Sector mix
No sector breakdown available for this fund.
Price chart
Returns
| 1 month | +1.66% |
| 3 months | +13.67% |
| 6 months | +20.88% |
| Year to date | +25.79% |
| 1 year | +34.68% |
| 3 years (ann.) | — |
| 5 years (ann.) | — |
| 10 years (ann.) | — |
Risk profile
| Volatility (1y, ann.) | 19.74% |
| Sharpe (1y) | 1.61 |
| Sharpe (3y) | — |
| Sortino (1y) | 2.93 |
| Max drawdown (1y) | -9.21% |
| Max drawdown (5y) | — |
| Max drawdown (full) | -9.21% |
| Beta vs S&P 500 (1y) | 1.26 |
| Correlation vs S&P 500 (1y) | 0.80 |
Technical outlook as of 2026-07-13
The Monte Carlo cone is drawn on the price chart above (Forecast overlay); RSI, MACD and the rest of the oscillators live in its indicator panels.
Full holdings
| Constituent | ISIN | Market value | Weight |
|---|---|---|---|
| Loading… | |||
Geographic exposure
Cost vs. peers
Comparison universe: 6,948 funds of the same asset class.
Cost impact calculator
Dividend history
Distributing share class Income is paid out to shareholders.
| Ex-date | Payment | Amount |
|---|---|---|
| 2025-12-22 | 2025-12-24 | USD 0.0581 |
ESG profile
Benchmark: average of 4,066 funds of the same asset class with derived ESG data.
Similar ETFs
| Fund | TER | AUM (USD) | Yield (TTM) | Return 1y | Sharpe 1y |
|---|---|---|---|---|---|
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.05% | +19.93% | 1.48 |
| Vanguard S&P 500 ETF VOO | 0.03% | 1.70T | 1.07% | +19.68% | 1.49 |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 1.09% | +19.68% | 1.49 |
| State Street SPDR S&P 500 ETF SPY | 0.09% | 789.23B | 1.00% | +19.71% | 1.49 |
| SPDR S&P 500 ETF Trust 1557.T | 0.09% | 789.09B | 0.49% | +37.54% | 2.26 |
| State Street SPDR S&P 500 ETF SPY.AX | 0.09% | 788.13B | 1.00% | +11.84% | 1.13 |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.61% | +20.58% | 1.21 |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 0.43% | +28.14% | 1.43 |
| Vanguard Growth ETF VUG | 0.03% | 393.80B | 0.39% | +16.85% | 0.99 |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 2.60% | +21.64% | 1.23 |
Cheaper alternatives
No fund of the class reaches 60% portfolio overlap — showing the cheapest funds of the class instead.
| Fund | TER | AUM (USD) | Overlap |
|---|---|---|---|
| Vanguard Small-Cap ETF VB | 0.03% | 182.70B | 2.9% |
| Vanguard Information Technology ETF VGT | 0.09% | 170.10B | 0.5% |
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 0.4% |
| iShares Russell 1000 Growth ETF IWF | 0.18% | 128.11B | 0.3% |
| Vanguard Mid-Cap ETF VO | 0.03% | 218.80B | 0.2% |

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
